Noliving Biotech

Nanjing Nuoling BioTechnology Co., Ltd. was registered and established in April 2018 in Nanjing's High-Tech Industrial Development Zone. The company is mainly engaged in the research, development, and production of new medical devices. The founding team has many years of study, research, and work experience in the United States, independently mastering core technologies, holding multiple patents, and maintaining deep collaboration with the University of Michigan laboratory, obtaining exclusive authorization from the university for related patents. Our core technology focuses on the generation and sustained release of nitric oxide (NO) and its medical applications. We will simultaneously develop and apply treatments for rare or complex diseases such as pulmonary hypertension, pulmonary fibrosis, chronic obstructive pulmonary emphysema, and diabetic foot on a global scale to address critical healthcare challenges. Additionally, our patented technology for generating NO gas is globally leading and is expected to disrupt traditional NO cylinder-based therapies, paving the way for numerous unmet clinical scenarios. Our innovative preparation and production technology for NO-releasing polymers also enables the antimicrobial function of NO to create industrial waves in areas like antimicrobial coatings, food preservation, and cosmetic health. With highly efficient R&D output and strong commercialization progress, the company currently has five pipeline products under development, two of which are expected to achieve commercialization within the next year, targeting a hundred-billion-yuan blue ocean market, with the potential to become a leading enterprise in the field of advanced gas therapy and detection.